REGN Share Price

Open 444.41 Change Price %
High 448.57 1 Day -3.12 -0.70
Low 442.01 1 Week -10.41 -2.30
Close 442.56 1 Month 7.92 1.82
Volume 643395 1 Year 71.03 19.12
52 Week High 543.55
52 Week Low 325.35
REGN Important Levels
Resistance 2 448.64
Resistance 1 446.14
Pivot 444.38
Support 1 438.98
Support 2 436.48
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
DEST 2.38 48.75%
HAUP 0.08 33.33%
SCHS 0.04 33.33%
SYNT 24.30 27.23%
SYNT 24.30 27.23%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PGRX 0.05 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)

REGN Technical Analysis 2
As on 17th Oct 2017 REGN Share Price closed @ 442.56 and we RECOMMEND Buy for LONG-TERM with Stoploss of 423.69 & Strong Sell for SHORT-TERM with Stoploss of 461.42 we also expect STOCK to react on Following IMPORTANT LEVELS.
REGN Target for October
1st Target up-side 490.19
2nd Target up-side 520.37
3rd Target up-side 550.56
1st Target down-side 404.05
2nd Target down-side 373.87
3rd Target down-side 343.68
REGN Other Details
Segment EQ
Market Capital 13942355968.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.regeneron.com
REGN Address
REGN
777 Old Saw Mill River Road
Tarrytown, NY 10591
United States
Phone: 914-347-7000
REGN Latest News
Interactive Technical Analysis Chart Regeneron Pharmaceuticals, Inc. ( REGN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Regeneron Pharmaceuticals, Inc.
REGN Business Profile
Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. As of December 31, 2011, the Company had two marketed products: EYLEA (aflibercept) Injection and ARCALYST (rilonacept) Injection for Subcutaneous Use. As of December 31, 2011, the Company had 13 product candidates in clinical development. Its Trap-based, late-stage programs are EYLEA, which is being developed for the treatment of additional serious eye diseases; ZALTRAP (aflibercept), known in the scientific literature as vascular endothelial growth factor (VEGF) trap, which is being developed in oncology in collaboration with Sanofi; and ARCALYST, which is being developed for the prevention of gout flares in patients initiating uric acid-lowering treatment.